FDA panel recommends label change

January 1, 2004
John Jesitus

John Jesitus is a medical writer based in Westminster, CO.

Washington, D.C. - Responding to concerns over increased malignancies seen in animal studies, a pediatric subcommittee of the FDA's Anti-Infective Drugs Advisory Committee said topical immunosuppressant labeling should include a warning against use in children under the age of two.